SONOMA PHARMACEUTICALS Earnings Preview: Recent $SNOA Insider Trading, Hedge Fund Activity, and More

Written by Emily J. Thompson, Senior Investment Analyst

SNOA-1.47%

Source: NASDAQ.COM

Updated: Jun 14 2025

0mins

Source: NASDAQ.COM

Earnings Release Announcement: Sonoma Pharmaceuticals ($SNOA) is set to announce its quarterly earnings on June 16th, with analysts predicting revenue of $4.5 million and a loss of $0.74 per share.
Additional Information: The article notes that it is not financial advice and encourages checking Quiver Quantitative for more data on stock activity, while also mentioning potential inaccuracies in the information provided.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SNOA?" and start using high-conviction signals backed by rigorous historical data.

SNOA

$3.34+Infinity%1D

Analyst Views on SNOA

About SNOA

Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for SNOA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy SNOA?

Get Started Free